Frag 176-191 and AOD-9604: dosage research profile
Search interest in frag 176 191 dosage and fragment 176 191 dosage is real, but the phrase bundles two related ideas: a C-terminal growth-hormone fragment studied for metabolic effects, and commercial research vials often labelled AOD-9604. This profile separates naming, mechanism, and literature-framed dosage context from grey-market protocol folklore. It is written for researchers who need an accurate on-ramp—not a substitute for primary papers or clinical supervision.
What Frag 176-191 is
Fragment 176-191 (often marketed as AOD-9604 when modified) is a C-terminal fragment of human growth hormone corresponding to residues 176–191 of the hGH sequence. Research interest focuses on lipolytic and anti-lipogenic signalling that appears partly separable from the full somatotropic axis effects of intact hGH. The fragment has been studied in animal models and limited human settings for body-composition endpoints; it is not FDA-approved as a weight-loss drug. Educational references should keep the naming clear: Frag 176-191 and AOD-9604 are related in the research literature but are not always identical preparations in grey-market catalogs.
How the fragment relates to growth hormone biology
Intact hGH acts through the growth hormone receptor and IGF-1 pathways with broad metabolic and anabolic effects. The 176–191 region has been investigated for adipose-tissue effects that do not fully recapitulate IGF-1 elevation seen with full-length hormone. That mechanistic separation is why the fragment appears in fat-loss research stacks rather than pure GH-secretagogue protocols. Readers comparing GHRP-2, Ipamorelin, and Frag 176-191 should treat them as different levers: secretagogues raise endogenous GH pulses; the fragment is a truncated sequence studied for local metabolic signalling.
Published research dosage context (not a protocol)
Human and preclinical literature cite a range of experimental exposures rather than a single standardised research-vial chart. Where human studies of AOD-9604 or related fragments report oral or injectable regimens, doses are study-specific and tied to endpoints such as body weight or lipid markers. Peptide Hub does not invent community forum milligram charts. When a vial SKU appears in the database (for example AOD-9604 entries), the dosing-guide fields show the research-range framing used on this site. Always prefer primary papers and registered trial protocols over secondary blogs.
Research dosage chart (literature-framed)
| Context | Typical literature framing | Notes |
|---|---|---|
| AOD-9604 / Frag-class injectable research refs | Study-specific mcg–mg ranges; often once daily in published protocols | Confirm salt, purity, and route in the primary paper |
| Comparison to GH secretagogues | Not interchangeable with Ipamorelin/GHRP-2 pulse dosing | Different mechanism family |
| Site dosing-guide SKUs | See dosing guide / database entry when present | Educational calculator only |
For GHRP-2 and Ipamorelin dosage charts, see the GHRP comparison guide and the CJC-1295 / Ipamorelin stack article.
Regulatory and quality caveats
Unapproved injectable peptides remain under multi-jurisdiction enforcement pressure in 2026. Fragment products sold as research chemicals are not evaluated like approved drugs. Identity, contamination, and mislabelling risks are material for any grey-market vial. This article is mechanism and literature orientation only.
Where this fits on Peptide Hub
Search demand for frag 176 191 dosage often lands on unrelated regulatory pages when no dedicated explainer exists. This profile closes that gap with accurate naming, mechanism contrast to GH secretagogues, and links into the dosing guide and existing GH-axis dosage articles. Readers looking for Ipamorelin dosage per day or fat-loss-oriented secretagogue charts should use the CJC/Ipamorelin and GHRP guides rather than treating Frag 176-191 as a drop-in substitute.
Editorial Note: This article is published for research and educational purposes only. Peptide Hub does not sell peptides, receive commissions from peptide vendors, or endorse any specific supplier. All compounds discussed are research peptides not approved for human therapeutic use except where specifically noted. This is not medical advice.
Sources
- Primary literature on hGH fragment 176–191 / AOD-9604 metabolic studies (PubMed; verify DOI per paper)
- GHRP-2 dosage comparison guide
- CJC-1295 / Ipamorelin stack
- Peptide Hub dosing guide